9-Hydroxycanthin-6-one

Name: 9-Hydroxycanthin-6-one
Brand: MedChemExpress
SKU: HY-N7183
Rating: 4.5 (0 reviews)

Cat. No.: HY-N7183: Data Sheet
SDS
Handling Instructions
FAQs
Technical Support

9-Hydroxycanthin-6-one is a β-carboline alkaloid. 9-Hydroxycanthin-6-one can be isolated from the roots of E. longifolia. 9-Hydroxycanthin-6-one inhibits TNF-α-induced activation of the NF-κB pathway. 9-Hydroxycanthin-6-one activates GSK3β independently of CK1α, drives phosphorylation and degradation of β-catenin, and inhibits the Wnt signaling pathway. 9-Hydroxycanthin-6-one exerts selective cytotoxicity against Wnt-dependent colon cancer cells. 9-Hydroxycanthin-6-one can be used in studies related to colon cancer.

For research use only. We do not sell to patients.

9-Hydroxycanthin-6-one Chemical Structure

CAS No. : 138544-91-9

Size	Stock	Quantity
1 mg	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
5 mg	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
10 mg	Get quote
50 mg	Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All GSK-3 Isoform Specific Products:

View All Isoforms

GSK-3 GSK-3α GSK-3β

View All Wnt Isoform Specific Products:

View All Isoforms

Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

GSK3β

Cellular Effect

Cell Line	Type	Value	Description	References
A549	ED₅₀	10 μg/mL Compound: 9-hydroxycanthin-6-one	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 14575431]
Breast carcinoma cell	IC₅₀	1.5 μg/mL Compound: 31	Cytotoxicity against human Breast cancer cell Cytotoxicity against human Breast cancer cell	[PMID: 34332400]
Calu-3	CC₅₀	> 100 μM Compound: Table 1, R10C2	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
Cancer cell lines	ED₅₀	2.6 μg/mL Compound: 3	Cytotoxicity against human breast cancer cells Cytotoxicity against human breast cancer cells	[PMID: 1800638]
Cancer cell lines	ED₅₀	3.8 μg/mL Compound: 3	Cytotoxicity against human lung cancer cells Cytotoxicity against human lung cancer cells	[PMID: 1800638]
Cancer cell lines	ED₅₀	4.8 μg/mL Compound: 3	Cytotoxicity against human colon cancer cells Cytotoxicity against human colon cancer cells	[PMID: 1800638]
Colon cancer cell line	IC₅₀	1.5 μg/mL Compound: 31	Cytotoxicity against human Colon cancer cell line Cytotoxicity against human Colon cancer cell line	[PMID: 34332400]
DLD-1	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against Wnt-dependent human DLD1 cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against Wnt-dependent human DLD1 cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 25905468]
Fibrosarcoma cell line	IC₅₀	1.5 μg/mL Compound: 31	Cytotoxicity against human Fibrosarcoma cell line Cytotoxicity against human Fibrosarcoma cell line	[PMID: 34332400]
HCT-116	IC₅₀	30 μM Compound: 1	Cytotoxicity against Wnt-dependent human HCT116 cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against Wnt-dependent human HCT116 cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 25905468]
HCT-8	CC₅₀	60.88 μM Compound: Table 1, R10C2	Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
HEK-293T	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against HEK293T cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against HEK293T cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 25905468]
HEK293	IC₅₀	36.7 μM Compound: 1	Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 25905468]
HEK293	IC₅₀	6.8 μM Compound: 1	Activation of GSK-3beta in HEK293 cells assessed as suppression of TCF/beta-catenin transcriptional activity after 24 hrs by SuperTOPFlash reporter gene assay Activation of GSK-3beta in HEK293 cells assessed as suppression of TCF/beta-catenin transcriptional activity after 24 hrs by SuperTOPFlash reporter gene assay	[PMID: 25905468]
HepG2	CC₅₀	> 100 μM Compound: Table 1, R10C2	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
KB	ED₅₀	2 μg/mL Compound: 3	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 1800638]
KB	IC₅₀	1.5 μg/mL Compound: 31	Cytotoxicity against human Vincristine-resistant KB cells Cytotoxicity against human Vincristine-resistant KB cells	[PMID: 34332400]
KB-V1	ED₅₀	> 20 μg/mL Compound: 3	Cytotoxicity against human KBV1 cells Cytotoxicity against human KBV1 cells	[PMID: 1800638]
Lung cancer cell line	IC₅₀	1.5 μg/mL Compound: 31	Cytotoxicity against human Lung cancer cell line Cytotoxicity against human Lung cancer cell line	[PMID: 34332400]
MCF7	ED₅₀	19.6 μg/mL Compound: 9-hydroxycanthin-6-one	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 14575431]
MRC5	CC₅₀	> 100 μM Compound: Table 1, R10C2	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
Melanoma cell	ED₅₀	5.4 μg/mL Compound: 3	Cytotoxicity against human melanoma cells Cytotoxicity against human melanoma cells	[PMID: 1800638]
Melanoma cell line	IC₅₀	1.5 μg/mL Compound: 31	Cytotoxicity against human Melanoma cell line Cytotoxicity against human Melanoma cell line	[PMID: 34332400]
P388	ED₅₀	1.5 μg/mL Compound: 3	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 1800638]
RKO	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against Wnt-independent human RKO cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against Wnt-independent human RKO cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 25905468]
SW480	IC₅₀	17.4 μM Compound: 1	Cytotoxicity against Wnt-independent human SW480 cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against Wnt-independent human SW480 cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 25905468]
Vero	CC₅₀	> 100 μM Compound: Table 1, R10C2	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]

In Vitro

9-Hydroxycanthin-6-one (3.8-30 μM; 30 min pretreatment, 4 h TNF-α stimulation) potently inhibits TNF-α-induced NF-κB activation in HEK-293/NF-κB-luc cells with an IC₅₀ of 3.8 μM, and exhibits no cytotoxicity at 30 μM^[1].
9-Hydroxycanthin-6-one (5-20 μM; 24 h) potently and selectively inhibits TCF/β-catenin transcriptional activity in STF/293 cells with an IC₅₀ of 6.8 μM, while preserving high cell viability^[2].
9-Hydroxycanthin-6-one (24 h) selectively inhibits the viability of Wnt-dependent human colon cancer cells (SW480, HCT116) with IC₅₀ values of 17.4 μM and 30.0 μM, respectively, while sparing Wnt-independent and noncancer cell lines^[2].
9-Hydroxycanthin-6-one (10-30 μM; 24 h) dose-dependently reduces total β-catenin levels (in whole cell, cytosolic, and nuclear fractions) and increases β-catenin phosphorylation at GSK3β target sites (Ser33/Ser37/Thr41) in SW480 cells, without altering CK1α-mediated β-catenin phosphorylation or total GSK3β/CK1α levels^[2].
9-Hydroxycanthin-6-one (30 μM; 24 h post-siRNA transfection) inhibits Wnt signaling in SW480 cells through GSK3β activation independent of CK1α, as it reduces β-catenin and increases GSK3β-mediated β-catenin phosphorylation even when CK1α is knocked down^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	SW480 cells
Concentration:	10, 20, 30 μM
Incubation Time:	24 h
Result:	Dose-dependently decreased total β-catenin protein levels in whole cellular, cytosolic, and nuclear fractions. Dose-dependently increased phosphorylated β-catenin at Ser33/Ser37/Thr41 (GSK3β phosphorylation sites). Had no effect on phosphorylated β-catenin at Ser45 (CK1α phosphorylation site) or total GSK3β/CK1α protein levels.

Western Blot Analysis^[2]

Cell Line:	SW480 cells
Concentration:	30 μM
Incubation Time:	24 h (post-siRNA transfection)
Result:	Decreased β-catenin levels and increased phosphorylated β-catenin at Ser33/Ser37/Thr41 in cells transfected with control siRNA. Attenuated reduction in β-catenin levels in cells transfected with GSK3β siRNA. Decreased phosphorylated GSK3β at Ser9 (inactive form) protein levels.\nDecreased β-catenin levels and increased phosphorylated β-catenin at Ser33/Ser37/Thr41 in both control siRNA-transfected and CK1α siRNA-transfected cells. Decreased phosphorylated GSK3β at Ser9 levels in CK1α siRNA-transfected cells.

In Vivo

9-Hydroxycanthin-6-one (100-300 μM; immersion in E3 medium; 4-30 hpf) inhibits Wnt signaling in zebrafish embryos, reduces Wnt target gene expression and pigment cell differentiation, and rescues BIO-induced eyeless phenotype, confirming its in vivo activity via GSK3β activation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	TOPdGFP transgenic strain; wild-type AB strain (embryos)^[2]
Dosage:	300 μM (TOPdGFP activity, Wnt target gene expression, pigment cell assessment); 100 μM (eyeless phenotype rescue)
Administration:	immersion in E3 medium; 10 hpf to 24 hpf (TOPdGFP activity); immersion in E3 medium; 4 hpf to 24 hpf (Wnt target gene expression); immersion in E3 medium; 4 hpf to 30 hpf (pigment cell assessment); immersion in E3 medium; 4 hpf to 30 hpf, co-administered with 0.5 μM BIO (eyeless phenotype rescue)
Result:	Reduced TOPdGFP activity in the midbrain tectum of 24 hpf embryos without inducing excess cell death (control MO group: 100% activity, n=10; p53 MO group: 100% activity, n=10). Reduced zic2a expression in the midbrain tectum of 24 hpf embryos (control MO group: 55% expression, n=6; p53 MO group: 54% expression, n=7). Reduced mitf expression in neural-crest cells of 24 hpf embryos (control MO group: 50% expression, n=7; p53 MO group: 60% expression, n=9). Reduced the number of pigment cells in the tails of 30 hpf embryos (100% reduction, n=10). Rescued the eyeless phenotype induced by 0.5 μM BIO in 30 hpf embryos, with 46% showing fully rescued eyes (n=6) and 54% showing slightly rescued eyes (n=7).

Molecular Weight

236.23

Formula

C₁₄H₈N₂O₂

CAS No.

138544-91-9

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1N2C3=C(N=CC=C3C4=C2C=C(O)C=C4)C=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Purity & Documentation

Data Sheet (283 KB) SDS (252 KB) Handling Instructions (2659 KB)

References

[1]. Thi Van Anh Tran, et al. NF-κB inhibitors from Eurycoma longifolia. J Nat Prod. 2014 Mar 28;77(3):483-8.

[Content Brief]

[2]. Ohishi K, et al. 9-Hydroxycanthin-6-one, a β-Carboline Alkaloid from Eurycoma longifolia, Is the First Wnt Signal Inhibitor through Activation of Glycogen Synthase Kinase 3β without Depending on Casein Kinase 1α. J Nat Prod. 2015 May 22;78(5):1139-46. [Content Brief]